A drug targeting a gene fusion that occurs across many types of cancer was effective in 93 percent of pediatric patients, researchers at UT Southwestern’s Simmons Cancer Center announced. The drug is the first cancer drug to receive FDA-breakthrough therapy designation for patients with a specific gene fusion, no matter the site of origin of the cancer. The research appears …
-
-
Peace for a Breast Cancer Survivor
-
What Would Motivate a Person to Action After a Breast Cancer Diagnosis
-
What’s on the Outside Doesn’t Really Matter to Many Breast Cancer Survivors
-
From a Breast Cancer Survivor: A Message to Telephone and Telemarketer Solicitors
-
Love After a Breast Cancer Diagnosis
